BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nintedanib (Ofev) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nintedanib (Ofev)\, from ClinicalTrials.g
 ov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04976036-1977@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nintedanib (Ofev): Phase 2 readout est. (NCT04976036)
DESCRIPTION:Nintedanib (Ofev)\, phase 2.\nStudy: Efficacy of Nintedanib for
  Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Pat
 ients\nEstimated primary completion: December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04976036
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07583589-1977@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Nintedanib (Ofev): Phase 2 readout est. (NCT07583589)
DESCRIPTION:Nintedanib (Ofev)\, phase 2\, Idiopathic Pulmonary Fibrosis.\nS
 tudy: Nintedanib With or Without Dextromethorphan in Patients With Idiopat
 hic Pulmonary Fibrosis (IPF)\nEstimated primary completion: 1 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-ofev#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07583589
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06297096-1977@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nintedanib (Ofev): Phase 3 readout est. (NCT06297096)
DESCRIPTION:Nintedanib (Ofev)\, phase 3\, Systemic Sclerosis.\nStudy: Study
  of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Scler
 osis and Interstitial Lung Disease\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-
 ofev#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06297096
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07335562-1977@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20281114
DTEND;VALUE=DATE:20281115
SUMMARY:Nintedanib (Ofev): Phase 3 readout est. (NCT07335562)
DESCRIPTION:Nintedanib (Ofev)\, phase 3\, Systemic Sclerosis.\nStudy: A Stu
 dy to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autole
 ucel / Zola-cel)\, CD19-CAR T Cells\, Versus Standard of Care in Participa
 nts With Active Systemic Sclerosis\nEstimated primary completion: 14 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-
 ofev#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07335562
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643091-1977@assetmemo.bio
DTSTAMP:20261121T005720Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Nintedanib (Ofev): Phase 2 readout est. (NCT06643091)
DESCRIPTION:Nintedanib (Ofev)\, phase 2.\nStudy: Nintedanib Treatment in Un
 icentric Castleman Disease\nEstimated primary completion: 1 May 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-ofev#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06643091
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
